iRhythm Technologies (IRTC) Expected to Announce Quarterly Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect iRhythm Technologies to announce earnings of $0.0155 per share and revenue of $222.23 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

iRhythm Technologies (NASDAQ:IRTC) last announced its earnings results on Thursday, August 6th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.62. iRhythm Technologies had a positive return on equity of 10.11% and a negative net margin of 1.69%. The business had revenue of $224.17 million for the quarter, compared to analysts’ expectations of $219.30 million. During the same quarter last year, the firm earned ($0.32) EPS. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, analysts expect iRhythm Technologies to post $0.54 EPS for the current fiscal year and $1.37 EPS for the next fiscal year.

iRhythm Technologies Trading Up 0.2%

Shares of NASDAQ:IRTC opened at $126.37 on Wednesday. The company has a market capitalization of $4.17 billion, a PE ratio of 274.28 and a beta of 1.39. The company has a current ratio of 3.86, a quick ratio of 3.74 and a debt-to-equity ratio of 3.50. iRhythm Technologies has a 12-month low of $100.70 and a 12-month high of $192.47. The business’s fifty day simple moving average is $115.02 and its 200-day simple moving average is $122.44.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Truist Financial raised their price objective on iRhythm Technologies from $160.00 to $168.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Piper Sandler began coverage on iRhythm Technologies in a research note on Friday, October 16th. They issued an “overweight” rating and a $160.00 target price on the stock. Weiss Ratings upgraded shares of iRhythm Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 27th. Wells Fargo & Company decreased their price target on shares of iRhythm Technologies from $168.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, October 6th. Finally, Wall Street Zen lowered shares of iRhythm Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $174.50.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a digital health company focused on the diagnosis and management of cardiac arrhythmias. The company provides ambulatory cardiac monitoring services that enable physicians to evaluate patients for conditions such as atrial fibrillation and other irregular heart rhythms.

Its principal offering is the Zio platform, which combines wearable electrocardiogram (ECG) monitoring devices with cloud-based data analysis and physician reports. Products in the platform include the Zio XT, an extended-wear monitor, and the Zio AT, which provides near-real-time monitoring capabilities.